Search Browse Earnings

PALVELLA THERAPEUTICS, INC.

Nasdaq:PVLA

Pharmaceutical Preparations·WAYNE, PA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

PALVELLA THERAPEUTICS, INC. — SlamSEC

Revenue

$27.2M

FY 2019

Adj. EBITDA

-$9.1M

-33.4% margin

FY 2024

Net Income

$18.7M

68.6% margin

FY 2024

EPS (Diluted)

$2.17

FY 2024

Stock Price

$136.70

+1.9%

2026-03-09

52W Range

$18.23 – $151.18

P/E Ratio

63.0x

Market Cap

$1.6B

Cash

$7.3M

FY 2024

Total Debt

—

Net Cash

$7.3M

FY 2019

Enterprise Value

$1.6B

Debt / EBITDA

0.8x

FY 2019

EV / EBITDA

-177.0x

Employees

—

CEO

Kaupinen Wes

CFO

Korenberg Matthew E